Shingrix

Shingrix Dosage/Direction for Use

recombinant varicella-zoster virus glycoprotein e antigen vaccine

Manufacturer:

GlaxoSmithKline Biologicals

Distributor:

Zuellig Pharma

Marketer:

GlaxoSmithKline
Full Prescribing Info
Dosage/Direction for Use
The immunisation schedules for Shingrix should be based on official recommendations.
Posology: The primary vaccination schedule consists of two doses of 0.5 ml each; an initial dose followed by a second dose 2 to 6 months later.
For subjects who are immunodeficient, immunosuppressed or likely to become immunosuppressed due to known disease or therapy, and whom would benefit from a shorter vaccination schedule, the second dose can be given 1 to 2 months after the initial dose (see Pharmacology: Pharmacodynamics under Actions).
The need for booster doses has not been established.
Shingrix can be given with the same schedule in individuals previously vaccinated with live attenuated HZ vaccine (see Pharmacology: Pharmacodynamics under Actions).
Shingrix is not indicated for prevention of primary varicella infection.
Method of administration: Shingrix is for intramuscular injection only, preferably in the deltoid muscle.
For instructions on reconstitution of the medicinal product before administration, see Instructions for Use and Handling under Cautions for Usage.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in